A novel anti-PD-L1 antibody tailored specifically to treat Neurodegenerative Diseases
IBC-Ab002 is uniquely designed to support its Mechanism of Action in Neurodegenerative diseases, including Alzheimer’s. It is a fully human therapeutic antibody with high affinity to block PD-L1 with Fc modifications that enable fast clearance from the circulation. In preclinical models of neurodegenerative diseases, short peripheral exposures of the antibody induced long-lasting beneficial changes in the CNS.
- Short half-life (fast clearance from the circulation)
- High binding affinity to human PD-L1
- No Fc effector cytotoxic activity (ADCC/CDC)
- Fully human; Fc-modified hIgG1
ImmunoBrain Approach with IBC-Ab002
IBC-Ab002 is uniquely positioned to tackle neurodegeneration with preclinical data suggesting simultaneous therapeutic effect on brain amyloid pathology, Tau pathologies, neuroinflammation, neuronal loss, and cognition.